Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
TMDX
SELLTransMedics Group, Inc. · Healthcare · United States · $2.5B · Avg Vol: $73M/d
34
StockRankGet insider-trade alerts
Q
72
V
42
M
11
P/E (TTM)
16.9x
ROE
45.2%
D/E
1.7x
Dividend %
—
COMPANY DESCRIPTION
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 93.5M | 241.6M | 441.5M | 605.5M | 86.4% | 635.9M | 733.0M | 867.8M | 19.7% |
| EPS | -1.23 | -0.77 | 1.07 | 5.60 | 423.4% | 4.34 | 3.75 | 6.10 | 4.4% |
| Shares | 32.1M | 32.7M | 33.6M | 34.3M | +6.6% | 34.6M | — | — | — |
| Debt | 67.6M | 515.9M | 518.3M | 519.3M | 97.4% | 863.4M | — | — | — |
| Equity | 187.4M | 137.2M | 228.6M | 473.1M | 36.2% | — | — | — | — |
| Op CF | -45.8M | -13.0M | 48.8M | 192.8M | 295.1% | 220.2M | — | — | — |
| Inv CF | 54.5M | -194.0M | -129.3M | -59.3M | — | — | — | — | — |
| Fin CF | 167.9M | 400.4M | 22.9M | 16.9M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+1.9%
SMA 50SMA 200
Close
$74.28
RSI (14)
57.9
52W High
$156.00
From 52W High
0.5%
SCORE BREAKDOWN
Quality
72
ROIC
12.4%80.4
ROE
45.2%96.4
GP/Assets
35.2%74.8
Op. Margin
7.6%61.5
FCF/Assets
10.2%87.3
Piotroski
783.4
Int. Cover
8.8x60.0
D/E Ratio
1.75x6.9
Current Ratio
6.74x79.3
Value
42
P/E (TTM)
16.9x68.0
EV/EBITDA
23.5x24.8
P/FCF
22.9x52.6
P/B
5.1x26.3
P/S
4.0x48.1
Div Yield
—N/A
Momentum
11
52W High %
48%23.7
RS 6M
-53%12.9
SMA 50/200
0.65x5.4
EPS Rev 4W
-16.1%2.6
EPS Rev 12W
-24.9%6.4
EPS Improve
-36%10.9
Q Growth
-72%4.7
FUNDAMENTALS
Market Cap
$2.5B
P/E (Forward)
26.6x
Gross Margin
59.1%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TMDX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| TMDX | TransMedics Group, Inc.(you) | $2.5B | 34 | SELL |
| ESTA | Establishment Labs Holdings Inc. | $2.7B | 36 | HOLD |
| NEOG | Neogen Corporation | $2.0B | 37 | HOLD |
| BFLY | Butterfly Network, Inc. | $1.7B | 36 | HOLD |
| IRTC | iRhythm Holdings, Inc. | $3.6B | 31 | SELL |
| ATEC | Alphatec Holdings, Inc. | $1.3B | 27 | SELL |
| TNDM | Tandem Diabetes Care, Inc. | $1.2B | 25 | SELL |
| LMRI | Lumexa Imaging Holdings, Inc. | $1.1B | 26 | SELL |
| AORT | Artivion, Inc. | $1.2B | 22 | SELL |
| GKOS | Glaukos Corporation | $9.0B | 35 | HOLD |
Peer medians: ROE -25.6% · P/E 27.7x · Gross margin 50.5%